2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
461
Melanoma
300
Squamous Cell Carcinoma of Head and Neck
234
Parkinson Disease 4, Autosomal Dominant Lewy Body
189
Neoplasms
185
Breast Neoplasms
162
Triple Negative Breast Neoplasms
161
Neoplasm Metastasis
156
Lung Neoplasms
146
Colorectal Neoplasms
142
Carcinoma, Renal Cell
132
Head and Neck Neoplasms
123
Stomach Neoplasms
104
Ovarian Neoplasms
100
Carcinoma, Transitional Cell
91
Urinary Bladder Neoplasms
81
Pancreatic Neoplasms
81
Carcinoma, Hepatocellular
74
Endometrial Neoplasms
72
Uterine Cervical Neoplasms
63
Esophageal Neoplasms
57
Recurrence
52
Prostatic Neoplasms
49
Sarcoma
43
Carcinoma
42
Glioblastoma
40
Carcinoma, Squamous Cell
39
Small Cell Lung Carcinoma
38
Hodgkin Disease
36
Cholangiocarcinoma
35
Interventions
enzalutamide
10
Abiraterone Acetate
6
rucaparib
2
Prednisone
2
Docetaxel
2
tildrakizumab
1
sabizabulin
1
pembrolizumab
1
fluzoparib
1
apatinib
1
abiraterone
1
Pluvicto
1
N-(2-(2,3-difluoro-6-benzylthio)-6-(3,4-dihydroxybutan-2-yloxy)pyrimidin-4-yl)azetidine-1-sulfonamide
1
Blood Specimen Collection
1
Biopsy
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Castration Resistant Prostate Cancer
×
pembrolizumab
×
Clear all
NCT03658447
2023-07-28
PRINCE
Peter MacCallum Cancer Centre, Australia
Phase 1/2
Completed
37 enrolled